Why the study?
Little is known about ARNI safety and effectiveness in real-world practice, and East Asian populations were underrepresented in the PARADIGM-HF trial.
Does angiotensin receptor neprilysin inhibitor improve clinical outcomes and left ventricular reverse remodeling in a real-world East Asian population with HFrEF?
Population
452 patients prescribed ARNI for at least 30 days across 3 medical institutes in Northern Taiwan
Design
Retrospective multicenter cohort study
Follow-up
12 months
Authors
Loading...
ARNI appeared safe for renal function and effective in sicker real-world HFrEF; leaves open confirmation versus PARADIGM-HF in prospective studies.
Does angiotensin receptor neprilysin inhibitor improve clinical outcomes and left ventricular reverse remodeling in a real-world East Asian population with HFrEF?
In a real-world Taiwanese cohort of HFrEF patients, ARNI therapy was safe and associated with significant improvements in LVEF and BNP at 12 months, despite patients having worse baseline renal function and receiving lower doses than in clinical trials.
Hsiao et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: